Glaucoma is the leading cause of irreversible blindness in the world. The condition causes damage to the optic nerve resulting in slow, painless vision loss over many years.
The National Institutes of Health (NIH) has selected the University of Pittsburgh to lead a trio of Phase 3 clinical trials involving COVID-19 patients. Collectively known as ACTIV-4 Antithrombotics, these trials will explore the use of blood thinners in saving lives and improving care, particularly among adult COVID-19 patients who are at risk of developing life-threatening blood clots.
EDC Faculty Goundappa K. Balasubramani, Ph.D., and Stephen R. Wisniewski, Ph.D. to lead $15.2 million NIH Grant for Glaucoma Laser Study
The National Eye Institute (NEI) funded the study “Clarifying the Optimal Application of SLT (COAST)” will compare standard SLT to low energy SLT and will also compare retreatment performed as needed when the effect wears off to retreatment annually to maintain eye pressure control without the need for medical therapy.
EDC faculty member G.K. Balasubramani elected to the International society for Influenza and other Respiratory Diseases
Dr. Balasubramani has been to the International society for Influenza and other Respiratory Diseases (ISIRV) for a three-year period.
Hormone replacement therapy is a common treatment for menopause-related symptoms, and new research from the University of Pittsburgh Graduate School of Public Health reinforces the importance of tailoring hormone therapy to each patient, based on her individual risk factors for cardiovascular disease.
EDC Co-Director Dr. Maria Mori Brooks will lead the data coordinating center for a $19.2 million international NIH study that will evaluate treatments for sickle cell disease
The clinical trial will assess two treatment strategies for adults with sickle cell disease. In particular, the trial will assess the effectiveness of adding red blood cell exchange transfusion (or erythrocytapheresis) to standard of care medical therapy as compared with the standard of care.
“Bariatric surgery is the most effective treatment for severe obesity. It results in sustained weight reduction and remission of diabetes and other health problems in the majority of patients,” said lead author Wendy King, Ph.D., associate professor in Pitt Public Health’s Department of Epidemiology.
Dr. King, along with senior author EDC Co-Director Steven Belle, found that measuring the percentage of weight regained following the maximum amount of weight lost after bariatric surgery can help predict a patient’s risk of several serious health problems.